On the other hand, the LACE-Bio pooled analysis, including data of 1543 patients participating in four clinical trials, showed that there is no difference in terms of outcomes in early-stage lung cancer patients with either wild-type or mutated KRAS [12]. Here, KRAS is linked to lung cancer.